To interfere and to anti-interfere: The interplay between hepatitis C virus and interferon

被引:70
作者
He, YP
Katze, MG
机构
[1] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA
[2] Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA
关键词
D O I
10.1089/088282402317340260
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
As popular strategies used by numerous viruses, interception of interferon (IFN) signaling and inhibition of IFN-induced antiviral functions allow viruses to evade the host immune response and set up successful infections. Hepatitis C virus (HCV), the leading cause of chronic liver disease worldwide and a major public health hazard, causes persistent infection in the majority of infected individuals. IFN-based therapies, currently the only ones available for HCV infection, have been unable to eliminate viral infection in the majority of patients, and many studies suggest that HCV possesses mechanisms to antagonize the IFN-induced antiviral response. Multiple viral, host, and IFN-associated factors have been implicated in the interplay between HCV and IFN. Two viral proteins, NS5A and E2, became the focus of much attention and extensive study because of their abilities to inhibit IFN-induced, double-stranded RNA-activated protein kinase (PKR), a major mediator of the IFN-induced biologic response, and to perturb the IFN signaling pathway. In this review, we discuss the significance of the interferon sensitivity determining region (ISDR) within NS5A, which has been the subject of intense debates. In addition, we discuss the potential mechanisms by which NS5A interferes with IFN signaling and the current working models. Further understanding of the molecular mechanisms underlying the interaction between HCV and IFN will likely facilitate improvement of current IFN-based therapies and development of novel treatments for the HCV pandemic. Future HCV research will benefit from both the development of efficient, convenient model systems for viral propagation, and the utilization of high throughput, genomic-scale approaches.
引用
收藏
页码:95 / 119
页数:25
相关论文
共 259 条
[1]   Fas antigen expression on hepatocytes predicts the short- and long-term response to interferon therapy in patients with chronic hepatitis C [J].
Abe, S ;
Kotoh, K ;
Arao, S ;
Tabaru, A ;
Otsuki, M .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2001, 36 (03) :326-331
[2]   Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins [J].
Aizaki, H ;
Saito, S ;
Ogino, T ;
Miyajima, N ;
Harada, T ;
Matsuura, Y ;
Miyamura, T ;
Kohase, M .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (12) :1111-1120
[3]   Epidemiology of hepatitis C [J].
Alter, MJ .
HEPATOLOGY, 1997, 26 (03) :S62-S65
[4]   Hepatitis C virus infection in the United States [J].
Alter, MJ .
JOURNAL OF HEPATOLOGY, 1999, 31 :88-91
[5]   Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum [J].
Ampurdanes, S ;
Olmedo, E ;
Maluenda, MD ;
Forns, X ;
LopezLabrador, FX ;
Costa, J ;
SanchezTapias, JM ;
deAnta, MTJ ;
Rodes, J .
JOURNAL OF HEPATOLOGY, 1996, 25 (06) :827-832
[6]   Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy [J].
Antonelli, G ;
Simeoni, E ;
Turriziani, O ;
Tesoro, R ;
Redaelli, A ;
Roffi, L ;
Antonelli, L ;
Pistello, M ;
Dianzani, F .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (03) :243-251
[7]   Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A [J].
Arima, N ;
Kao, CY ;
Licht, T ;
Padmanabhan, R ;
Sasaguri, Y ;
Padmanabhan, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12675-12684
[8]   The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α [J].
Barnard, P ;
McMillan, NAJ .
VIROLOGY, 1999, 259 (02) :305-313
[9]   Novel cell culture systems for the hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
ANTIVIRAL RESEARCH, 2001, 52 (01) :1-17
[10]  
BARTON AL, 1995, AM J CLIN PATHOL, V103, P419